NCT05667441

Brief Summary

The AMD-Life study investigates which strategies (personalized risk-profiling including genetic testing and/or coaching) motivate AMD patients to change their lifestyle.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2021

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

November 21, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 28, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 14, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 14, 2025

Completed
Last Updated

September 11, 2025

Status Verified

September 1, 2025

Enrollment Period

4 years

First QC Date

November 21, 2022

Last Update Submit

September 5, 2025

Conditions

Keywords

Age-Related Macular DegenerationLifestyleLifestyle changeGenetic testingPersonalized risk-profilingGut microbiomeCoaching

Outcome Measures

Primary Outcomes (2)

  • Change in lifestyle score

    Change in lifestyle as measured by online questionnaires, scale from 0-13 in which 13 represents a healthy lifestyle

    0 and 12 months: intervention phase

  • Change in lifestyle score

    Change in lifestyle as measured by online questionnaires, scale from 0-13 in which 13 represents a healthy lifestyle

    12 and 24 months: follow-up phase

Study Arms (3)

Standard recommendations

ACTIVE COMPARATOR

The first group (n=50) will receive standard care recommendations (according to Netherlands Scientific Society of Ophthalmology 2014, 'Richtlijn Leeftijdsgebonden Maculadegeneratie;): refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish; and recommendations for supplementation with antioxidants according an established formula.

Combination Product: Standard lifestyle recommendations + dietary supplementation

Standard recommendations + Risk profiling

ACTIVE COMPARATOR

The second group (n=50) receives standard care plus personalized risk profiling. A risk scoring based on currently available literature for lifestyle and genetic risk will be used to determine personalized risks of conversion to late AMD. Individuals will be informed about their own risk profile and a personalized strategy will be communicated.

Combination Product: Standard lifestyle recommendations + dietary supplementationCombination Product: Risk profiling

Standard recommendations + Risk profiling + Additional coaching

ACTIVE COMPARATOR

The third group (n=50) receives standard care (see 1); personalized risk profiling (see 2); and coaching. A coach will employ behavioral change techniques (BCT) to enhance adherence using motivational interviews, feedback on behavior; and focus on the advantages of following recommendations.

Combination Product: Standard lifestyle recommendations + dietary supplementationCombination Product: Risk profilingBehavioral: Coaching

Interventions

refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula

Standard recommendationsStandard recommendations + Risk profilingStandard recommendations + Risk profiling + Additional coaching
Risk profilingCOMBINATION_PRODUCT

Personalized risk profiling for lifestyle and genetics.

Standard recommendations + Risk profilingStandard recommendations + Risk profiling + Additional coaching
CoachingBEHAVIORAL

Coaching

Standard recommendations + Risk profiling + Additional coaching

Eligibility Criteria

Age55 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Early/Intermediate AMD or unilateral late AMD with minimal vision 0.8

You may not qualify if:

  • Participation in other intervention studies for AMD
  • Living in retirement homes (difficulty in implementation of diet)
  • Diagnosis of dementia (because of unreliable dietary recall)
  • Persons with macular pathology other than AMD hindering appropriate grading of the macula
  • Persons who are illiterate and have no independent trusted person with them to explain the informed consent form.
  • Persons diagnosed with liver and kidney insufficiency.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Erasmus Medical Center

Rotterdam, Netherlands

Location

Related Links

MeSH Terms

Conditions

Macular Degeneration

Interventions

Dietary Supplements

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • C.C.W. Klaver, Prof. Dr.

    Erasmus Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Open label, randomized, clinical trial with 3 arms. Total study duration 2 years: intervention period for 1 year and a follow-up period of 1 year with no intervention for all study arms.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. dr. C.C.W. Klaver

Study Record Dates

First Submitted

November 21, 2022

First Posted

December 28, 2022

Study Start

August 1, 2021

Primary Completion

July 14, 2025

Study Completion

July 14, 2025

Last Updated

September 11, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations